These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1347220)

  • 1. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls.
    Hartikainen P; Reinikainen KJ; Soininen H; Sirviö J; Soikkeli R; Riekkinen PJ
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):53-68. PubMed ID: 1347220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
    Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.
    Sjögren M; Davidsson P; Wallin A; Granérus AK; Grundström E; Askmark H; Vanmechelen E; Blennow K
    Dement Geriatr Cogn Disord; 2002; 13(2):112-8. PubMed ID: 11844893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Chen X; Hu Y; Cao Z; Liu Q; Cheng Y
    Front Immunol; 2018; 9():2122. PubMed ID: 30283455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.
    Jolkkonen J; Soininen H; Halonen T; Ylinen A; Laulumaa V; Laakso M; Riekkinen P
    J Neurol Neurosurg Psychiatry; 1986 Dec; 49(12):1374-7. PubMed ID: 2433403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.
    Steinacker P; Verde F; Fang L; Feneberg E; Oeckl P; Roeber S; Anderl-Straub S; Danek A; Diehl-Schmid J; Fassbender K; Fliessbach K; Foerstl H; Giese A; Jahn H; Kassubek J; Kornhuber J; Landwehrmeyer GB; Lauer M; Pinkhardt EH; Prudlo J; Rosenbohm A; Schneider A; Schroeter ML; Tumani H; von Arnim CAF; Weishaupt J; Weydt P; Ludolph AC; Yilmazer Hanke D; Otto M;
    J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):239-247. PubMed ID: 29142138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases.
    Masuda T; Itoh J; Koide T; Tomidokoro Y; Takei Y; Ishii K; Tamaoka A
    J Clin Neurosci; 2017 Jan; 35():47-49. PubMed ID: 27756506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-beta-hydroxylase and acetylcholinesterase activities of cerebrospinal fluid in Alzheimer's disease.
    Soininen H; Pitkänen A; Halonen T; Riekkinen PJ
    Acta Neurol Scand; 1984 Jul; 70(1):29-34. PubMed ID: 6147948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.
    Hartikainen P; Soininen H; Reinikainen KJ; Sirviö J; Soikkeli R; Riekkinen PJ
    J Neural Transm Gen Sect; 1991; 84(1-2):103-17. PubMed ID: 1675857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF neurotransmitter markers in Alzheimer's disease.
    Beal MF; Growdon JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):259-70. PubMed ID: 2879317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.
    Oeckl P; Steinacker P; von Arnim CA; Straub S; Nagl M; Feneberg E; Weishaupt JH; Ludolph AC; Otto M
    J Proteome Res; 2014 Nov; 13(11):4518-25. PubMed ID: 25091646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and dementia: clinical and neurochemical correlations.
    Strittmatter MM; Cramer H
    Neuroreport; 1992 May; 3(5):413-6. PubMed ID: 1378766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical differences in the CSF between Binswanger's and Alzheimer's disease.
    Strittmatter M; Hamann GF; Grauer MT; Cramer H; Schimrigk K
    Dement Geriatr Cogn Disord; 1997; 8(1):34-42. PubMed ID: 8997550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.